Loading: 100%
CAMBREX CORP logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 1,295 (as per Q1 2016)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker CBMno data available
Financial year endsFY ends End of Decemberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 173542495663
datesClosing price (adj.)
13.10.201753.70
11.10.201753.80
04.10.201755.35
27.09.201755.45
20.09.201753.45
13.09.201751.10
06.09.201751.30
30.08.201752.20
23.08.201751.75
16.08.201753.45
09.08.201752.60
02.08.201761.95
26.07.201759.00
19.07.201758.55
12.07.201758.10
05.07.201758.00
27.06.201759.60
20.06.201759.40
13.06.201757.40
06.06.201755.90
30.05.201754.20
23.05.201752.60
16.05.201754.60
09.05.201753.45
02.05.201756.65
25.04.201756.80
18.04.201755.65
11.04.201756.80
04.04.201755.35
28.03.201751.40
21.03.201750.25
14.03.201749.75
07.03.201752.50
28.02.201756.35
21.02.201754.90
14.02.201752.65
07.02.201754.80
31.01.201752.45
24.01.201753.35
17.01.201754.05
10.01.201756.00
03.01.201753.40
27.12.201654.85
19.12.201653.20
12.12.201653.40
05.12.201650.15
28.11.201649.10
21.11.201649.50
14.11.201653.35
07.11.201646.50
31.10.201640.30
24.10.201641.55
17.10.201640.80
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
53.70n/a
Market Capitalisation
in million USD
1,717n/a
Enterprise Value
in million USD
1,632n/a
Common Shares Outstanding
as per Apr 28, 2016
31,978,467n/a
Preferred Shares Outstanding
as per Apr 28, 2016
n/a
Average Basic Shares Outstanding
TTM
31,592,000n/a
Average Diluted Shares Outstanding
TTM
32,708,250n/a
Index Membership
n/a
Business Summary
Cambrex Corp is a biotechnology company focused on developing and commercializing new and generic therapeutics. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 86n/a
Receivables 47n/a
Total Current Assets 284n/a
PP&E 204n/a
Total Assets 544n/a
Accounts Payable 39n/a
Current Debt 0n/a
Total Current Liabilities 105n/a
Long-Term Debt 0n/a
Total Liabilities 209n/a
Total Equity 335n/a
Cash Flow
Depreciation & Amortisation 22n/a
Change in Working Capital 22n/a
Operating Cash Flow 138n/a
Net Change in PP&E and Intangibles -67n/a
Investing Cash Flow -68n/a
Dividends Paid 0n/a
Financing Cash Flow -54n/a
Total Change in Cash 18n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share 10.61n/a
FCF per Share n/a
Dividends per Share 0.00n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value 5.06n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value 0.20n/a
Other Ratios
Current Ratio 271.5%n/a
Liabilities to Equity Ratio 62.4%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Revenue
707
682
768
833
955
1,126
1,302
Sales & Services Revenue
0
0
0
0
0
0
0
Financing Revenue
0
0
0
0
0
0
0
Other Revenue
0
0
0
0
0
0
0
Cost of revenue
-164
-160
-182
-186
-215
-251
-256
Cost of Goods & Services
0
0
0
0
0
0
0
Cost of Financing Revenue
0
0
0
0
0
0
0
Cost of Other Revenue
0
0
0
0
0
0
0
Gross Profit
543
522
586
647
740
875
1,046
Other Operating Income
0
0
0
0
0
0
0
Operating Expenses
-44
-44
-50
-55
-58
-66
-70
Selling, General & Administrative
-36
-34
-39
-45
-48
-52
-58
Selling & Marketing
0
0
0
0
0
0
0
General & Administrative
0
0
0
0
0
0
0
Research & Development
-8
-10
-11
-10
-10
-13
-13
Depreciation & Amortization
0
0
0
0
0
0
0
Provision For Doubtful Accounts
0
0
0
0
0
0
0
Other Operating Expense
0
0
0
0
0
0
0
Operating Income (Loss)
499
478
536
593
682
809
976
Non-Operating Income (Loss)
-4
-5
-4
-4
-5
-7
-1
Interest Expense, net
-5
-4
-2
-2
-2
-2
-2
Interest Expense
0
0
0
0
0
0
0
Interest Income
0
0
0
0
0
0
0
Other Investment Income (Loss)
0
0
0
0
0
0
0
Foreign Exchange Gain (Loss)
0
0
0
0
0
0
0
Income (Loss) from Affiliates
0
0
-2
-2
-2
-5
0
Other Non-Operating Income (Loss)
1
-1
0
0
0
0
0
Pretax Income (Loss), Adjusted
495
472
532
588
677
803
974
Abnormal Gains (Losses)
0
0
0
0
5
-6
16
Acquired In-Process R&D
0
0
0
0
0
0
0
Merger / Acquisition Expense
0
0
0
0
0
0
0
Abnormal Derivatives
0
0
0
0
0
0
0
Disposal of Assets
0
0
0
0
0
0
0
Early extinguishment of Debt
0
0
0
0
0
0
0
Asset Write-Down
0
0
0
0
0
0
0
Impairment of Goodwill & Intangibles
0
0
0
0
0
0
0
Sale of Business
0
0
0
0
0
0
0
Legal Settlement
0
0
0
0
0
0
0
Restructuring Charges
0
0
0
0
0
0
0
Sale of and Unrealized Investments
0
0
0
0
0
0
0
Insurance Settlement
0
0
0
0
0
0
0
Other Abnormal Items
0
0
0
0
0
0
0
Pretax Income (Loss)
495
473
532
588
682
797
990
Income Tax (Expense) Benefit, net
-12
-6
-6
32
-15
13
-32
Current Income Tax
0
0
0
0
0
0
0
Deferred Income Tax
0
0
0
0
0
0
0
Tax Allowance/Credit
0
0
0
0
0
0
0
Income (Loss) from Affiliates, net of taxes
0
0
0
0
0
0
0
Income (Loss) from Continuing Operations
483
467
526
620
667
809
957
Net Extraordinary Gains (Losses)
0
0
-3
-1
-4
-1
0
Discontinued Operations
0
0
-3
-1
-4
-1
0
XO & Accounting Charges & Other
0
0
0
0
0
0
0
Income (Loss) Including Minority Interest
483
467
523
619
663
808
957
Minority Interest
0
0
0
0
0
0
0
Net Income
483
467
523
619
663
808
957
Preferred Dividends
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Net Income Available to Common Shareholders
483
467
523
619
663
808
957
Remarks
restated on Feb 7, 2012 n/a
calculated values,
restated on Feb 7, 2013 n/a
calculated values,
restated on Feb 11, 2014 n/a
calculated values,
restated on Feb 6, 2015 n/a
calculated values,
restated on Feb 9, 2016 n/a
calculated values,
restated on Feb 9, 2016 n/a
calculated values,
restated on Feb 9, 2016 n/a
calculated values,
Balance SheetBS data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Assets
Cash, Cash Equivalents & Short Term Investments
n/a
30
32
24
23
46
44
Cash & Cash Equivalents
n/a
30
32
24
23
46
44
Short Term Investments
n/a
0
0
0
0
0
0
Accounts & Notes Receivable
n/a
39
37
43
71
77
91
Accounts Receivable, Net
n/a
39
37
43
71
77
91
Notes Receivable, Net
n/a
0
0
0
0
0
0
Unbilled Revenues
n/a
0
0
0
0
0
0
Inventories
n/a
61
62
71
90
86
110
Raw Materials
n/a
0
0
0
0
0
0
Work In Process
n/a
0
0
0
0
0
0
Finished Goods
n/a
0
0
0
0
0
0
Other Inventory
n/a
0
0
0
0
0
0
Other Short Term Assets
n/a
5
6
6
19
15
14
Prepaid Expenses
n/a
5
6
4
6
5
7
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Assets Held-for-Sale
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
0
0
0
0
0
Income Taxes Receivable
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Miscellaneous Short Term Assets
n/a
0
0
2
13
11
7
Total Current Assets
n/a
135
137
144
203
224
259
Property, Plant & Equipment, Net
n/a
150
140
152
172
164
186
Property, Plant & Equipment
n/a
0
0
0
0
0
0
Accumulated Depreciation
n/a
0
0
0
0
0
0
Long Term Investments & Receivables
n/a
0
0
0
0
0
0
Long Term Investments
n/a
0
0
0
0
0
0
Long Term Marketable Securities
n/a
0
0
0
0
0
0
Long Term Receivables
n/a
0
0
0
0
0
0
Other Long Term Assets
n/a
66
67
90
84
99
60
Intangible Assets
n/a
5
4
4
4
9
7
Goodwill
n/a
38
37
37
39
44
32
Other Intangible Assets
n/a
0
0
0
0
0
0
Prepaid Expense
n/a
0
0
0
0
0
0
Deferred Tax Assets
n/a
0
7
31
20
42
19
Derivative & Hedging Assets
n/a
0
0
0
0
0
0
Prepaid Pension Costs
n/a
0
0
0
0
0
0
Discontinued Operations
n/a
0
0
0
0
0
0
Investments in Affiliates
n/a
20
15
15
13
0
0
Miscellaneous Long Term Assets
n/a
4
3
3
8
5
2
Total Noncurrent Assets
n/a
217
206
242
255
263
246
Total Assets
n/a
352
343
386
458
487
506
Liabilities and owners' equity
Payables & Accruals
n/a
53 52983000
58 58073000
71 70913000
77 77150000
84 84495000
84 83504000
Accounts Payable
n/a
19 19480000
21 21200000
28 27612000
29 29052000
44 43670000
39 39257000
Accrued Taxes
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Interest & Dividends Payable
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Payables & Accruals
n/a
34 33503000
37 36873000
43 43301000
48 48098000
41 40825000
44 44247000
Short Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
30 30000000
Short Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Short Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Current Portion of Long Term Debt
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Short Term Liabilities
n/a
0 0
1 1060000
12 11570000
20 20121000
14 14095000
16 16298000
Deferred Revenue
n/a
0 0
1 1060000
12 11570000
20 20121000
14 14095000
16 16298000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Short Term Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Current Liabilities
n/a
53 52983000
59 59133000
82 82483000
97 97271000
99 98590000
130 129802000
Long Term Debt
n/a
116 115900000
98 98000000
64 64000000
79 79250000
60 60000000
0 0
Long Term Borrowings
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Long Term Capital Leases
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Long Term Liabilities
n/a
75 75233000
85 85357000
76 75951000
71 71296000
77 76771000
65 64902000
Accrued Liabilities
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Pension Liabilities
n/a
44 43921000
52 52089000
55 55373000
40 40123000
51 50949000
43 42661000
Pensions
n/a
44 43921000
52 52089000
55 55373000
40 40123000
51 50949000
43 42661000
Other Post-Retirement Benefits
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Compensation
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Revenue
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Deferred Tax Liabilities
n/a
18 17893000
23 23330000
10 10383000
13 12835000
10 10249000
8 7735000
Derivatives & Hedging
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Discontinued Operations
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Miscellaneous Long Term Liabilities
n/a
13 13419000
10 9938000
10 10195000
18 18338000
16 15573000
15 14506000
Total Noncurrent Liabilities
n/a
191 191133000
183 183357000
140 139951000
151 150546000
137 136771000
65 64902000
Total Liabilities
n/a
244 244116000
242 242490000
222 222434000
248 247817000
235 235361000
195 194704000
Preferred Equity
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Share Capital & Additional Paid-In Capital
n/a
104 104411000
105 104789000
107 107342000
113 112988000
123 122549000
135 135333000
Common Stock
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Additional Paid in Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Other Share Capital
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Treasury Stock
n/a
-17 -16876000
-16 -15821000
-15 -15217000
-15 -14984000
-15 -14823000
-15 -14747000
Retained Earnings
n/a
32 31992000
43 42960000
105 105263000
131 131178000
188 188481000
246 245698000
Other Equity
n/a
-12 -11892000
-32 -31587000
-34 -34091000
-19 -18962000
-45 -44981000
-55 -55449000
Equity Before Minority Interest
n/a
108 107635000
100 100341000
163 163297000
210 210220000
251 251226000
311 310835000
Minority Interest
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Total Equity
n/a
108 107635000
100 100341000
163 163297000
210 210220000
251 251226000
311 310835000
Total Liabilities & Equity
n/a
352 351751000
343 342831000
386 385731000
458 458037000
487 486587000
506 505539000
Remarks restated on n/a restated on Feb 7, 2012 n/a restated on Feb 7, 2013 n/a restated on Feb 11, 2014 n/a restated on Feb 6, 2015 n/a restated on Feb 9, 2016 n/a restated on Apr 29, 2016 n/a
Cash Flow StatementCF data quality: 100% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
No data available for the selected time periods
in million USD FY '09FY '10FY '11FY '12FY '13FY '14FY '15
Net Income/Starting Line
10
10
11
62
26
57
57
Net Income
0
0
0
0
0
0
0
Net Income From Discontinued Operations
0
0
0
0
0
0
0
Other Adjustments
0
0
0
0
0
0
0
Depreciation & Amortization
21
22
23
22
22
24
22
Non-Cash Items
10
4
3
-34
0
-12
32
Stock-Based Compensation
0
0
0
0
0
0
0
Deferred Income Taxes
0
0
0
0
0
0
0
Other Non-Cash Adjustments
0
0
0
0
0
0
0
Change in Working Capital
-7
-12
1
-3
-10
-2
-26
(Increase) Decrease in Accounts Receivable
0
0
0
0
0
0
0
(Increase) Decrease in Inventories
0
0
0
0
0
0
0
Increase (Decrease) in Accounts Payable
0
0
0
0
0
0
0
Increase (Decrease) in Other
0
0
0
0
0
0
0
Net Cash From Discontinued Operations (operating)
0
0
-1
-4
-2
-2
-2
Cash from Operating Activities
34
23
38
44
37
65
84
Change in Fixed Assets & Intangibles
-13
-13
-15
-18
-55
-21
-60
Disposition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Disposition of Fixed Assets
0
0
0
0
0
0
0
Disposition of Intangible Assets
0
0
0
0
0
0
0
Acquisition of Fixed Assets & Intangibles
0
0
0
0
0
0
0
Purchase of Fixed Assets
0
0
0
0
0
0
0
Acquisition of Intangible Assets
0
0
0
0
0
0
0
Other Change in Fixed Assets & Intangibles
0
0
0
0
0
0
0
Net Change in Long Term Investment
0
0
0
0
0
0
0
Decrease in Long Term Investment
0
0
0
0
0
0
0
Increase in Long Term Investment
0
0
0
0
0
0
0
Net Cash From Acquisitions & Divestitures
0
-26
-1
0
0
-2
0
Net Cash from Divestitures
0
0
0
0
0
0
0
Cash for Acqusition of Subsidiaries
0
0
0
0
0
0
0
Cash for Joint Ventures
0
0
0
0
0
0
0
Net Cash from Other Acquisitions
0
0
0
0
0
0
0
Other Investing Activities
0
0
0
-2
-2
-1
0
Net Cash From Discontinued Operations (investing)
0
0
0
0
0
0
0
Cash from Investing Activities
-13
-39
-15
-20
-57
-25
-60
Dividends Paid
-1
0
0
0
0
0
0
Cash From (Repayment of) Debt
-3
-5
-18
-34
15
-19
-30
Cash From (Repayment of) Short Term Debt, net
0
0
0
0
0
0
0
Cash From (Repayment of) Long Term Debt, net
0
0
0
0
0
0
0
Repayments of Long Term Debt
0
0
0
0
0
0
0
Cash From Long Term Debt
0
0
0
0
0
0
0
Cash From (Repurchase of) Equity
0
0
0
1
3
4
6
Increase in Capital Stock
0
0
0
1
3
4
6
Decrease in Capital Stock
0
0
0
0
0
0
0
Other Financing Activities
0
0
-2
0
0
1
1
Net Cash From Discontinued Operations (financing)
0
0
0
0
0
0
0
Cash from Financing Activities
-4
-5
-20
-33
18
-15
-23
Net Cash Before Disc. Operations and FX
18
-21
3
-9
-2
26
1
Change in Cash from Disc. Operations and Other
0
0
0
0
0
0
0
Net Cash Before FX
18
-21
3
-9
-2
26
1
Effect of Foreign Exchange Rates
2
-2
-1
1
1
-3
-2
Net Changes in Cash
20
-23
2
-8
-1
23
-2
Remarks
restated on Feb 7, 2012 n/a
calculated values,
restated on Feb 7, 2013 n/a
calculated values,
restated on Feb 11, 2014 n/a
calculated values,
restated on Feb 6, 2015 n/a
calculated values,
restated on Feb 9, 2016 n/a
calculated values,
restated on Feb 9, 2016 n/a
calculated values,
restated on Feb 9, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo